Molecular Oncology
Volume 1, Issue 4 , Pages 406-412 , April 2008

Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib

  • Gary M. Clark

      Affiliations

    • Corresponding Author InformationTel.: +1 303 546 7633; fax: +1 303 546 7889.

Received 11 November 2007 ,Revised 3 December 2007 ,Accepted 4 December 2007.

References 

  1. Birnbaum A, Ready N. Gefitinib therapy for non-small cell lung cancer. Curr. Treat. Options Oncol. 2005;6:75–81
  2. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1:49–67
  3. Clark GM, Zborowski DM, Santabárbara P, Ding K, Whitehead M, Seymour L, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Clin. Lung Cancer. 2006;7:389–394
  4. Clark GM, Zborowski DM, Culbertson JL, Whitehead M, Savoie M, Seymour L, et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J. Thorac. Oncol. 2006;1:837–846
  5. Fleming TR. Objective response rate as a surrogate end point: a commentary. J. Clin. Oncol. 2005;23:4845–4846
  6. Goodin S. Erlotinib: optimizing therapy with predictors of response?. Clin. Cancer Res. 2006;12:2961–2963
  7. Hsieh R-K, Lim K-H, Kuo H-T, Tzen C-Y, Huang M-J. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small lung cancer. Chest. 2005;128:317–321
  8. Matsuo K, Ito H, Yatabe Y, Hiraki A, Hirose K, Wakai K, et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci. 2007;98:96–101
  9. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann M-H, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J. Clin. Oncol. 2005;23:165–174
  10. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al Erlotinib in previously treated non-small-cell lung cancer. N. Engl. Med. 2005;353:123–132
  11. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–1537
  12. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J. Thorac. Oncol. 2006;1:231–239

☆ Presented in part at the 13th Danish Cancer Society Symposium: From the Bench to the Bedside and Back, Copenhagen, Denmark, August 27–29, 2007.

PII: S1574-7891(07)00102-0

doi: 10.1016/j.molonc.2007.12.001

Molecular Oncology
Volume 1, Issue 4 , Pages 406-412 , April 2008

Article Tools

* Image Usage & Resolution